Recherches "plusieurs pathologies" ALCYTA (IC 2020-12) Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA Paris, Saint-Cloud NICOLAS GIRARD, NICOLAS GIRARD
Appareil Digestif ProActIF-01 ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers Paris, Saint-Cloud
Recherches "plusieurs pathologies" TG4001.12 A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies and expansion cohort to oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) Paris CHRISTOPHE LE TOURNEAU
Appareil Digestif ADAGE - Prodige 34 Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over. Saint-Cloud
Appareil Digestif AMEBICA - Prodige 38 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours. Saint-Cloud
Appareil Digestif IROCAS - PRODIGE 52 A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting Saint-Cloud
Pédiatrie Tumeurs solides MICCHADO (IC 2017-02) Molecular and Immunological Characterisation of high risk CHildhood Cancer At DiagnOsis, treatment and follow-up - Biological evaluation in children, adolescents and young adults. Paris GUDRUN SCHLEIERMACHER
Appareil Digestif PACHA 01 Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial Saint-Cloud
Recherches "plusieurs pathologies" AcSé Pembrolizumab Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types. Saint-Cloud CAROLE SOUSSAIN
Recherches "plusieurs pathologies" AcSé Vemurafenib Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Saint-Cloud ETIENNE BRAIN